Cardiometabolic Therapeutics Market Size, Scope, Revenue Report 2026 to 2035
Segmentations of Cardiometabolic Therapeutics Market:
Cardiometabolic Therapeutics Market, by Therapeutic Area -
- Obesity & Weight Management
- Type 2 Diabetes Mellitus (T2DM)
- Atherosclerotic Cardiovascular Disease (ASCVD) & Lipid Management
- Heart Failure (HFrEF, HFmrEF, HFpEF)
- Chronic Kidney Disease (CKD) – Cardiorenal
- Hypertension (Essential & Resistant)
- Metabolic Liver Disease (MASLD/MASH)
Cardiometabolic Therapeutics Market, by Drug Class -
- GLP-1 Receptor Agonists (Single Agonists)
- Dual GLP-1/GIP Agonists
- Triple GLP-1/GIP/Glucagon Agonists
- Amylin Analogs & GLP-1/Amylin Combinations
- SGLT2 Inhibitors
- PCSK9 Inhibitors (Monoclonal Antibodies & siRNA)
- Lipoprotein(a) [Lp(a)] Targeted Therapies (ASO, siRNA, Small Molecules)
- ApoC-III / ANGPTL3 Inhibitors
- CETP Inhibitors
- THR-β Agonists (MASH-specific)
- FGF21 Analogs
- Aldosterone Synthase Inhibitors
- Non-Steroidal Mineralocorticoid Receptor Antagonists (MRAs)
- Other Novel Agents
- Gene editing therapies
- NLRP3 inhibitors
- CB1 inverse agonists
- Oral small-molecule non-peptide GLP-1s
Cardiometabolic Therapeutics Market, by Molecule Type -
- Small Molecules
- Peptides / Biologics
- Monoclonal Antibodies
- siRNA / RNAi Therapeutics
- Antisense Oligonucleotides (ASOs)
- Gene-Editing Therapies
- Fixed-Dose Combinations
Cardiometabolic Therapeutics Market, by Route of Administration -
- Oral
- Subcutaneous Injectable
- Intravenous
Cardiometabolic Therapeutics Market, by Dosing Frequency -
- Once Daily
- Once Weekly
- Once Monthly or Less Frequent (including quarterly)
- Other (twice daily, biannual)
Cardiometabolic Therapeutics Market, by Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East and Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cardiometabolic Therapeutics Market Snapshot
Chapter 4. Global Cardiometabolic Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter’s Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2026-2035
4.8. Global Cardiometabolic Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2025-2035
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2025)
4.10. Epidemiology & patient pool analysis
4.11. Treatment pathway & unmet need mapping
4.12. Pipeline & biologics/targeted therapy landscape
4.13. Reimbursement & access analysis
4.14. Use/impact of AI on Cardiometabolic Therapeutics Market Industry Trends
Chapter 5. Cardiometabolic Therapeutics Market Segmentation 1: By Therapeutic Area, Estimates & Trend Analysis
5.1. Market Share by Therapeutic Area, 2025 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Therapeutic Area:
5.2.1. Obesity & Weight Management
5.2.2. Type 2 Diabetes Mellitus (T2DM)
5.2.3. Atherosclerotic Cardiovascular Disease (ASCVD) & Lipid Management
5.2.4. Heart Failure (HFrEF, HFmrEF, HFpEF)
5.2.5. Chronic Kidney Disease (CKD) – Cardiorenal
5.2.6. Hypertension (Essential & Resistant)
5.2.7. Metabolic Liver Disease (MASLD/MASH)
Chapter 6. Cardiometabolic Therapeutics Market Segmentation 2: By Drug Class, Estimates & Trend Analysis
6.1. Market Share by Drug Class, 2025 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Drug Class:
6.2.1. GLP-1 Receptor Agonists (Single Agonists)
6.2.2. Dual GLP-1/GIP Agonists
6.2.3. Triple GLP-1/GIP/Glucagon Agonists
6.2.4. Amylin Analogs & GLP-1/Amylin Combinations
6.2.5. SGLT2 Inhibitors
6.2.6. PCSK9 Inhibitors (Monoclonal Antibodies & siRNA)
6.2.7. Lipoprotein(a) [Lp(a)] Targeted Therapies (ASO, siRNA, Small Molecules)
6.2.8. ApoC-III / ANGPTL3 Inhibitors
6.2.9. CETP Inhibitors
6.2.10. THR-β Agonists (MASH-specific)
6.2.11. FGF21 Analogs
6.2.12. Aldosterone Synthase Inhibitors
6.2.13. Non-Steroidal Mineralocorticoid Receptor Antagonists (MRAs)
6.2.14. Other Novel Agents
6.2.14.1. Gene editing therapies
6.2.14.2. NLRP3 inhibitors
6.2.14.3. CB1 inverse agonists
6.2.14.4. Oral small-molecule non-peptide GLP-1s
Chapter 7. Cardiometabolic Therapeutics Market Segmentation 3: By Molecule Type, Estimates & Trend Analysis
7.1. Market Share by Molecule Type, 2025 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Molecule Type:
7.2.1. Small Molecules
7.2.2. Peptides / Biologics
7.2.3. Monoclonal Antibodies
7.2.4. siRNA / RNAi Therapeutics
7.2.5. Antisense Oligonucleotides (ASOs)
7.2.6. Gene-Editing Therapies
7.2.7. Fixed-Dose Combinations
Chapter 8. Cardiometabolic Therapeutics Market Segmentation 4: By Route of Administration, Estimates & Trend Analysis
8.1. Market Share by Route of Administration, 2025 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Route of Administration:
8.2.1. Oral
8.2.2. Subcutaneous Injectable
8.2.3. Intravenous
Chapter 9. Cardiometabolic Therapeutics Market Segmentation 5: By Dosing Frequency, Estimates & Trend Analysis
9.1. Market Share by Dosing Frequency, 2025 & 2035
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2035 for the following Dosing Frequency:
9.2.1. Once Daily
9.2.2. Once Weekly
9.2.3. Once Monthly or Less Frequent (including quarterly)
9.2.4. Other (twice daily, biannual)
Chapter 10. Cardiometabolic Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Cardiometabolic Therapeutics Market, Regional Snapshot 2025 & 2035
10.2. North America
10.2.1. North America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
10.2.1.1. The US
10.2.1.2. Canada
10.2.1.3. Mexico
10.2.2. North America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2022-2035
10.2.3. North America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2022-2035
10.2.4. North America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2022-2035
10.2.5. North America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
10.2.6. North America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2022-2035
10.3. Europe
10.3.1. Europe Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
10.3.1.1. Germany
10.3.1.2. The UK
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2022-2035
10.3.3. Europe Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2022-2035
10.3.4. Europe Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2022-2035
10.3.5. Europe Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
10.3.6. Europe Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2022-2035
10.4. Asia Pacific
10.4.1. Asia Pacific Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
10.4.1.1. China
10.4.1.2. Japan
10.4.1.3. India
10.4.1.4. South Korea
10.4.1.5. South East Asia
10.4.1.6. Rest of Asia Pacific
10.4.2. Asia Pacific Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2022-2035
10.4.3. Asia Pacific Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2022-2035
10.4.4. Asia Pacific Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2022-2035
10.4.5. Asia Pacific Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
10.4.6. Asia Pacific Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2022-2035
10.5. Latin America
10.5.1. Latin America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
10.5.1.1. Brazil
10.5.1.2. Argentina
10.5.1.3. Rest of Latin America
10.5.2. Latin America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2022-2035
10.5.3. Latin America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2022-2035
10.5.4. Latin America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2022-2035
10.5.5. Latin America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
10.5.6. Latin America Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2022-2035
10.6. Middle East & Africa
10.6.1. Middle East & Africa Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2035
10.6.1.1. GCC Countries
10.6.1.2. South Africa
10.6.1.3. Rest of Middle East and Africa
10.6.2. Middle East & Africa Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2022-2035
10.6.3. Middle East & Africa Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2022-2035
10.6.4. Middle East & Africa Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2022-2035
10.6.5. Middle East & Africa Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
10.6.6. Middle East & Africa Cardiometabolic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Dosing Frequency, 2022-2035
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Eli Lilly and Company
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Novo Nordisk A/S
11.2.3. AstraZeneca PLC
11.2.4. Boehringer Ingelheim
11.2.5. Amgen Inc.
11.2.6. Novartis AG
11.2.7. Pfizer Inc.
11.2.8. Sanofi
11.2.9. Merck & Co., Inc. (MSD)
11.2.10. Madrigal Pharmaceuticals
11.2.11. Zealand Pharma
11.2.12. Roche
11.2.13. Viking Therapeutics
11.2.14. Structure Therapeutics
11.2.15. Esperion Therapeutics
11.2.16. Lexicon Pharmaceuticals
11.2.17. Alnylam Pharmaceuticals
11.2.18. Arrowhead Pharmaceuticals
11.2.19. Ionis Pharmaceuticals
11.2.20. Silence Therapeutics
11.2.21. Verve Therapeutics
11.2.22. CRISPR Therapeutics
11.2.23. NewAmsterdam Pharma
11.2.24. Innovent Biologics
11.2.25. Hansoh Pharmaceutical
11.2.26. Sciwind Biosciences
11.2.27. MetaVia Inc.
11.2.28. Ventyx Biosciences
11.2.29. Insilico Medicine
11.2.30. Bayer
11.2.31. Bristol-Myers Squibb
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Cardiometabolic Therapeutics Market is estimated to grow rapidly with at a 10.5% CAGR during the forecast period for 2026 to 2035.
Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca PLC, Boehringer Ingelheim, Amgen Inc., Novartis AG, Pfizer Inc., Sanofi, Merck & Co., Inc. (MSD), Madrigal Pharmaceuticals and Others.
Cardiometabolic Therapeutics Market is segmented into Therapeutic Area, Drug Class, Molecule Type, Route of Administration, Dosing Frequency and Other.
North America region is leading the Cardiometabolic Therapeutics Market.